|Articles|October 14, 2019

Yourway Mitigates Uncertainty of Brexit

Yourway, courier and clinical packager offering integrated clinical trial supply chain solutions, announced its establishment of a new location within the European Union providing storage and distribution services, including secondary packaging capabilities, located 40 minutes from the Vienna, Austria airport in Bratislava, Slovakia. This move was designed to ensure uninterrupted support for clients’ trials in both the UK and mainland Europe if the United Kingdom leaves the EU on the current deadline of October 31, especially in the event of a no-deal Brexit. 

“The new location in Europe mitigates the uncertainty of Brexit for our clients, in order to service their clinical trial needs. It includes Qualified Person (QP) release services within Europe prior to release for use in a Clinical Trial, as required by Clinical Trial Directive 2001/20/EC and Annex 13 to the European GMP Guide.” said Yourway President and Founder, Gulam Jaffer. 

“Through our Project Managers and QP release personnel, and use of our global network of GMP depots, we can assure safe and timely delivery of clinical trial materials to patients,” he added.

Yourway provides a full range of temperature-controlled solutions designed to protect clinical trial shipments from the time an order is received through to delivery on time for patient dosing protocols. It is also offering an integrated supply chain with no differences in quality to traditional multi-provider models in this market.


Related to this article

The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.